Commentary Open Access
Volume 3 | Issue 4 | DOI: https://doi.org/10.33696/cancerimmunol.3.055
Humanized Chimeric Antigen Receptor (CAR) T cells
Pouya Safarzadeh Kozani1,2,#, Pooria Safarzadeh Kozani3,#, Roddy S. O’Connor4,5,*
- 11 Department of Medical Biotechnology, Faculty of Paramedicine, Guilan University of Medical Sciences, Rasht, P.O. Box 41446/66949, Iran
- 2Student Research Committee, Medical Biotechnology Research Center, School of Nursing, Midwifery, and Paramedicine, Guilan University of Medical Sciences, Rasht, P.O. Box 41446/66949, Iran
- 3Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, P.O. Box 14115/111, Iran
- 4Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA
- 5Department of Pathology and Laboratory Medicine, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
- #These authors share first authorship
Corresponding Author
Roddy S. O’Connor, oconnorr@pennmedicine.upenn.edu
Received Date: September 09, 2021
Accepted Date: October 26, 2021
Kozani PS, Kozani PS, O’Connor RS. Humanized Chimeric Antigen Receptor (CAR) T cells. J Cancer Immunol. 2021; 3(4): 183-187.
Copyright: © 2021 Kozani PS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Prevalence of Symptom Clusters in Cancer Patients at First Presentation in Palliative Care Clinic as per Different Disease Groups
Cancer has its own disease burden and patients usually suffer from symptom clusters when they are referred for palliative treatment. Identification of symptom cluster trajectories will help clinician to take into account measures that can optimize quality of life of palliative patients. Therefore the aim of this paper is to determine the overall prevalence of symptoms and symptoms clusters in different disease groups according to etiology at the time of first visit to Palliative care clinic by using HIS Palliative First Assessment note indicating Edmonton symptom scale.
Chimeric Antigen Receptor CAR NK Cells Emerging Immunotherapy for the Treatment of Cancer
Although NK cells are recognized as effector lymphocytes of the innate immune system, they also regulate the adaptive immune response by releasing inflammatory cytokines and developing immunological memory. Unlike other lymphocytes such as T or B cells, NK cells do not express rearrangeable, antigen-specific receptors.
Therapeutic Values of Ketamine for COVID-19-Cared Patients: An Expert’s Point of View
Ketamine has long been used in the field of anesthesia [1]. Its rapid and long-acting analgesic effects associated with its dissociative properties have also established its use in prehospital and emergency department patients.
Gender Disparities in Outcomes Following Pulmonary Embolism Treatment in the Intensive Care Unit; A Multi-center Retrospective Cohort Study
Pulmonary embolism (PE) is a blockage of blood flow in the pulmonary artery bed that can result in a life-threatening and potentially reversible right ventricular failure [1]. PE remains one of the leading causes of poor prognosis and death, particularly when a shock or right ventricular failure occurs [2]. According to studies, PE is generally manifested in a nonspecific manner
Multidisciplinary Acute Care of Central Retinal Artery Occlusion with a Stroke Paradigm: A Call to Action
Central retinal artery occlusion (CRAO) is a painless ophthalmologic emergency with potential for irreversible vision loss. Similar to ischemic stroke, CRAO occurs when there is sudden obstruction of the central retinal artery, leading to ischemic injury to the retina and subsequent cell death. Continuous occlusion and ischemia of the retina progresses to permanent damage to retinal cells and loss of vision.